Abstract
SummaryThe increase in availability of actinobacterial whole genome sequences has revealed huge numbers of specialised metabolite biosynthetic gene clusters, encoding a range of bioactive molecules such as antibiotics, antifungals, immunosuppressives and anticancer agents. Yet the majority of these clusters are not expressed under standard laboratory conditions in rich media. Emerging data from studies of specialised metabolite biosynthesis suggest that the diversity of regulatory mechanisms is greater than previously thought and these act at multiple levels, through a range of signals such as nutrient limitation, intercellular signalling and competition with other organisms. Understanding the regulation and environmental cues that lead to the production of these compounds allows us to identify the role that these compounds play in their natural habitat as well as provide tools to exploit this untapped source of specialised metabolites for therapeutic uses. Here, we provide an overview of novel regulatory mechanisms that act in physiological, global and cluster‐specific regulatory manners on biosynthetic pathways in Actinobacteria and consider these alongside their ecological and evolutionary implications.
Highlights
Actinobacteria exhibit staggering diversity in terms of their biosynthetic capability for specialised metabolitesReceived 8 September, 2017; revised 7 February, 2018; accepted 9 February, 2018. *For correspondence
Genome sequencing efforts have revealed that there are a large number of specialised metabolite biosynthetic gene clusters (BGCs) in actinobacterial genomes that encode for the production of potentially useful metabolites which are not actively expressed under commonly used laboratory conditions
The availability of numerous Streptomyces genome sequences suggests that this is a gross underestimation of their biosynthetic capabilities and that there is still a large reservoir of untapped bioactive molecules to be discovered from these organisms
Summary
Actinobacteria exhibit staggering diversity in terms of their biosynthetic capability for specialised metabolitesReceived 8 September, 2017; revised 7 February, 2018; accepted 9 February, 2018. *For correspondence. PpGpp synthesis has been previously shown to be required for antibiotic production under conditions of nitrogen limitation at least in S. coelicolor (Chakraburtty and Bibb, 1997; Hesketh et al, 2001), no evidence of the direct effect of ppGpp synthesis on the regulation of a specialised metabolite biosynthetic pathway had been provided until recently.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
